All News
Filter News
Found 809,003 articles
-
Amgen (JOBS): Denosumab Prostate Cancer Trial Meets Goals
2/9/2010
-
Popular GlaxoSmithKline Antidepressant Interferes With Cancer Drug, Institute for Clinical Evaluative Sciences Study
2/9/2010
-
University of California, Los Angeles (UCLA) Researchers Reveal 3-D Structure Of Bullet-Shaped Virus With Potential To Fight Cancer, HIV
2/9/2010
-
Hearts Actually Can Break, Minneapolis Heart Institute And Johns Hopkins University Studies
2/9/2010
-
An Early Warning System for Cancer, University of Copenhagen Study
2/9/2010
-
Plant Derivative Could Help Refine Cancer Treatment, Medical College of Georgia Study
2/9/2010
-
SPO Medical Launches its Technology in Sports Market
2/9/2010
-
Lupin Ltd. Receives FDA Approval for Amlodipine/Benazepril Capsules
2/9/2010
-
Sagent Pharmaceuticals, Inc. Announces FDA Approval of Labetalol Hydrochloride Injection, USP
2/9/2010
-
Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
2/9/2010
-
ChemGenex Pharmaceuticals Limited: Extreme Weather in Washington D.C. has Postponed the FDA's Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010
2/9/2010
-
Chelsea Therapeutics, Inc. Announces Advancements in Neurogenic Orthostatic Hypotension Registration Program
2/9/2010
-
Nymox Pharmaceutical Provides Update on Pivotal Phase 3 Trials for BPH Drug
2/9/2010
-
Dynavax Technologies Corporation Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)
2/9/2010
-
Penwest Pharmaceutical Initiates Second Phase IIa Clinical Trial for A0001
2/9/2010
-
Provectus Pharmaceuticals Inc.'s PV-10 and Radiotherapy Featured in Peer Reviewed Journal
2/9/2010
-
ThromboGenics NV: Positive Microplasmin Phase II Data Published in Ophthalmology
2/9/2010
-
XOMA (US) LLC Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
2/9/2010
-
Palatin Technologies Announces Dosing of Subcutaneous Bremelanotide Trial in Men
2/9/2010
-
Stem Cell Therapeutics Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
2/9/2010